• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受静脉-动脉体外膜肺氧合治疗患者的年龄及相关预后——体外生命支持组织注册研究分析

Age and associated outcomes among patients receiving venoarterial extracorporeal membrane oxygenation-analysis of the Extracorporeal Life Support Organization registry.

作者信息

Fernando Shannon M, MacLaren Graeme, Barbaro Ryan P, Mathew Rebecca, Munshi Laveena, Madahar Purnema, Fried Justin A, Ramanathan Kollengode, Lorusso Roberto, Brodie Daniel, McIsaac Daniel I

机构信息

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Department of Critical Care, Lakeridge Health Corporation, Oshawa, ON, Canada.

出版信息

Intensive Care Med. 2023 Dec;49(12):1456-1466. doi: 10.1007/s00134-023-07199-1. Epub 2023 Oct 4.

DOI:10.1007/s00134-023-07199-1
PMID:
37792052
Abstract

PURPOSE

Venoarterial extracorporeal membrane oxygenation (V-A ECMO) can be used to support severely ill patients with cardiogenic shock. While age is commonly used in patient selection, little is known regarding its association with outcomes in this population. We sought to evaluate the association between increasing age and outcomes following V-A ECMO.

METHODS

We used individual-level patient data from 440 centers in the international Extracorporeal Life Support Organization registry. We included all adult patients receiving V-A ECMO from 2017 to 2019. The primary outcome was hospital mortality. Secondary outcomes included a composite of complications following initiation of V-A ECMO. We conducted Bayesian analyses of the relationship between increasing age and outcomes of interest.

RESULTS

We included 15,172 patients receiving V-A ECMO. Of these, 8172 (53.9%) died in hospital. For the analysis conducted using weakly informed priors, and as compared to the reference category of age 18-29, the age bracket of 30-39 (odds ratio [OR] 0.94, 95% credible interval [CrI] 0.79-1.10) was not associated with hospital mortality, but age brackets 40-49 (odds ratio [OR] 1.26, 95% CrI: 1.08-1.47), 50-59 (OR 1.78, 95% CrI: 1.55-2.06), 60-69 (OR 2.24, 95% CrI: 1.94-2.59), 70-79 (OR 2.90, 95% CrI: 2.49-3.39) and ≥ 80 (OR 4.02, 95% CrI: 3.13-5.20) were independently associated with increasing hospital mortality. Similar results were found in the analysis conducted with an informative prior, as well as between increasing age and post-ECMO complications.

CONCLUSIONS

Among patients receiving V-A ECMO for cardiogenic shock, increasing age is strongly associated with increasing odds of death and complications, and this association emerges as early as 40 years of age.

摘要

目的

静脉-动脉体外膜肺氧合(V-A ECMO)可用于支持重症心源性休克患者。虽然年龄常用于患者选择,但对于其与该人群预后的关联知之甚少。我们旨在评估年龄增长与V-A ECMO治疗后预后之间的关联。

方法

我们使用了国际体外生命支持组织注册中心440个中心的个体水平患者数据。纳入了2017年至2019年期间接受V-A ECMO治疗的所有成年患者。主要结局是医院死亡率。次要结局包括启动V-A ECMO后并发症的综合情况。我们对年龄增长与感兴趣的结局之间的关系进行了贝叶斯分析。

结果

我们纳入了15172例接受V-A ECMO治疗的患者。其中,8172例(53.9%)在医院死亡。在使用弱信息先验进行的分析中,与18 - 29岁的参考类别相比,30 - 39岁年龄组(比值比[OR] 0.94,95%可信区间[CrI] 0.79 - 1.10)与医院死亡率无关,但40 - 49岁年龄组(OR 1.26,95% CrI:1.08 - 1.47)、50 - 59岁年龄组(OR 1.78,95% CrI:1.55 - 2.06)、60 - 69岁年龄组(OR 2.24,95% CrI:1.94 - 2.59)、70 - 79岁年龄组(OR 2.90,95% CrI:2.49 - 3.39)和≥80岁年龄组(OR 4.02,95% CrI:3.13 - 5.20)均与医院死亡率增加独立相关。在使用信息性先验进行的分析以及年龄增长与ECMO后并发症之间的分析中也发现了类似结果。

结论

在接受V-A ECMO治疗的心源性休克患者中,年龄增长与死亡和并发症几率增加密切相关,且这种关联早在40岁时就已出现。

相似文献

1
Age and associated outcomes among patients receiving venoarterial extracorporeal membrane oxygenation-analysis of the Extracorporeal Life Support Organization registry.接受静脉-动脉体外膜肺氧合治疗患者的年龄及相关预后——体外生命支持组织注册研究分析
Intensive Care Med. 2023 Dec;49(12):1456-1466. doi: 10.1007/s00134-023-07199-1. Epub 2023 Oct 4.
2
Age and associated outcomes among patients receiving venovenous extracorporeal membrane oxygenation for acute respiratory failure: analysis of the Extracorporeal Life Support Organization registry.急性呼吸衰竭行静脉-静脉体外膜肺氧合治疗患者的年龄及相关结局:体外生命支持组织登记研究分析。
Intensive Care Med. 2024 Mar;50(3):395-405. doi: 10.1007/s00134-024-07343-5. Epub 2024 Feb 20.
3
Clinical utility of venoarterial-extracorporeal membrane oxygenation (VA-ECMO) in patients with drug-induced cardiogenic shock: a retrospective study of the Extracorporeal Life Support Organizations' ECMO case registry.药物性心原性休克患者应用静脉-动脉体外膜肺氧合(VA-ECMO)的临床效果:体外生命支持组织 ECMO 病例登记库的一项回顾性研究。
Clin Toxicol (Phila). 2020 Jul;58(7):705-710. doi: 10.1080/15563650.2019.1676896. Epub 2019 Oct 16.
4
Timing of Initiation of Extracorporeal Membrane Oxygenation Support and Outcomes Among Patients With Cardiogenic Shock.心源性休克患者体外膜肺氧合支持启动时机与预后
J Am Heart Assoc. 2024 Feb 6;13(3):e032288. doi: 10.1161/JAHA.123.032288. Epub 2024 Jan 19.
5
Cardiogenic shock severity and mortality in patients receiving venoarterial extracorporeal membrane oxygenator support.接受静脉-动脉体外膜肺氧合支持的患者的心源性休克严重程度和死亡率。
Eur Heart J Acute Cardiovasc Care. 2022 Dec 27;11(12):891-903. doi: 10.1093/ehjacc/zuac119.
6
Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization.体外膜肺氧合在心源休克患者中作为桥接治疗的应用:来自体外生命支持组织的见解。
Circ Heart Fail. 2022 Jan;15(1):e008777. doi: 10.1161/CIRCHEARTFAILURE.121.008777. Epub 2021 Dec 9.
7
Venoarterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock in Elderly Patients: Trends in Application and Outcome From the Extracorporeal Life Support Organization (ELSO) Registry.老年患者顽固性心源性休克的静脉-动脉体外膜肺氧合:体外生命支持组织(ELSO)注册研究中的应用趋势与结局
Ann Thorac Surg. 2017 Jul;104(1):62-69. doi: 10.1016/j.athoracsur.2016.10.023. Epub 2017 Jan 26.
8
Clinical predictors of in-hospital mortality in venoarterial extracorporeal membrane oxygenation.静脉-动脉体外膜肺氧合治疗中院内死亡的临床预测因素
J Card Surg. 2020 Oct;35(10):2512-2521. doi: 10.1111/jocs.14758. Epub 2020 Aug 13.
9
Exposure to Arterial Hyperoxia During Extracorporeal Membrane Oxygenator Support and Mortality in Patients With Cardiogenic Shock.体外膜肺氧合支持期间暴露于动脉性高氧与心源性休克患者的死亡率。
Circ Heart Fail. 2023 Apr;16(4):e010328. doi: 10.1161/CIRCHEARTFAILURE.122.010328. Epub 2023 Mar 5.
10
Mortality Predictors in Elderly Patients With Cardiogenic Shock on Venoarterial Extracorporeal Life Support. Analysis From the Extracorporeal Life Support Organization Registry.老年心源性休克患者应用体外膜肺氧合支持的死亡率预测因素。来自体外生命支持组织登记处的分析。
Crit Care Med. 2021 Jan 1;49(1):7-18. doi: 10.1097/CCM.0000000000004695.

引用本文的文献

1
Role of age in prognostication of hospital mortality in postcardiotomy patients supported with extracorporeal membrane oxygenation.年龄在体外膜肺氧合支持下的心内直视术后患者医院死亡率预后中的作用。
Postepy Kardiol Interwencyjnej. 2025 May 29;21(2):221-228. doi: 10.5114/aic.2025.151722. eCollection 2025 Jun.
2
ICU capacity, ICU staffing, and postcardiotomy ECMO outcomes in China: a multilevel cross-sectional study.中国重症监护病房(ICU)容量、ICU人员配备及心脏术后体外膜肺氧合(ECMO)治疗结果:一项多水平横断面研究
Crit Care. 2025 Jul 3;29(1):268. doi: 10.1186/s13054-025-05443-2.
3
Characterization of pathogenic bacterial distribution in extracorporeal membrane oxygenation-related nosocomial infections and the prognostic value of early inflammatory biomarkers for infection survival.

本文引用的文献

1
Prognostic models for mortality risk in patients requiring ECMO.需要 ECMO 支持的患者死亡率风险预测模型。
Intensive Care Med. 2023 Feb;49(2):131-141. doi: 10.1007/s00134-022-06947-z. Epub 2023 Jan 4.
2
Association of Extracorporeal Membrane Oxygenation With New Mental Health Diagnoses in Adult Survivors of Critical Illness.体外膜肺氧合与危重症成年幸存者新心理健康诊断的关联。
JAMA. 2022 Nov 8;328(18):1827-1836. doi: 10.1001/jama.2022.17714.
3
Frailty in intensive care medicine must be measured, interpreted and taken into account!
体外膜肺氧合相关医院感染中病原菌分布特征及早期炎症生物标志物对感染存活的预后价值
Front Microbiol. 2025 Mar 4;16:1555701. doi: 10.3389/fmicb.2025.1555701. eCollection 2025.
4
Indications for extracorporeal membrane oxygenation in older adult patients with accidental hypothermia and hemodynamic instability.老年意外低温合并血流动力学不稳定患者体外膜肺氧合的适应证
BMC Emerg Med. 2025 Mar 13;25(1):44. doi: 10.1186/s12873-025-01202-2.
5
Geospatial Access to Extracorporeal Membrane Oxygenation in the United States.美国体外膜肺氧合治疗的地理空间可及性
Crit Care Med. 2025 Feb 17;53(4):e874-83. doi: 10.1097/CCM.0000000000006607.
6
Extracorporeal membrane oxygenation for adults with respiratory failure secondary to cardiorespiratory disease: evolving indications and clinical practice.用于患有心肺疾病继发呼吸衰竭的成人的体外膜肺氧合:不断演变的适应症和临床实践
Breathe (Sheff). 2025 Jan 21;21(1):240119. doi: 10.1183/20734735.0119-2024. eCollection 2025 Jan.
7
Outcome and complications in postcardiotomy cardiogenic shock treated with extracorporeal life support - a systematic review and meta-analysis.体外生命支持治疗心脏术后心源性休克的结局与并发症——一项系统评价和荟萃分析
BMC Anesthesiol. 2025 Jan 17;25(1):29. doi: 10.1186/s12871-025-02898-2.
8
COMPREHENSIVE CHARACTERIZATION OF CYTOKINES IN PATIENTS UNDER EXTRACORPOREAL MEMBRANE OXYGENATION: EVIDENCE FROM INTEGRATED BULK AND SINGLE-CELL RNA SEQUENCING DATA USING MULTIPLE MACHINE LEARNING APPROACHES.体外膜肺氧合患者细胞因子的综合表征:来自使用多种机器学习方法的综合批量和单细胞RNA测序数据的证据
Shock. 2025 Feb 1;63(2):267-281. doi: 10.1097/SHK.0000000000002425. Epub 2024 Aug 23.
9
Acute brain injury risk prediction models in venoarterial extracorporeal membrane oxygenation patients with tree-based machine learning: An Extracorporeal Life Support Organization Registry analysis.基于树的机器学习的静脉-动脉体外膜肺氧合患者急性脑损伤风险预测模型:体外生命支持组织注册分析
JTCVS Open. 2024 Jun 8;20:64-88. doi: 10.1016/j.xjon.2024.06.001. eCollection 2024 Aug.
10
Management of cardiogenic shock: state-of-the-art.心原性休克的治疗:最新进展。
Intensive Care Med. 2024 Nov;50(11):1814-1829. doi: 10.1007/s00134-024-07618-x. Epub 2024 Sep 10.
重症医学中的衰弱必须得到测量、解读并加以考虑!
Intensive Care Med. 2023 Jan;49(1):87-90. doi: 10.1007/s00134-022-06887-8. Epub 2022 Oct 7.
4
Inotropes, vasopressors, and mechanical circulatory support for treatment of cardiogenic shock complicating myocardial infarction: a systematic review and network meta-analysis.正性肌力药、血管加压药和机械循环支持治疗心肌梗死后并发的心源性休克:系统评价和网络荟萃分析。
Can J Anaesth. 2022 Dec;69(12):1537-1553. doi: 10.1007/s12630-022-02337-7. Epub 2022 Oct 4.
5
Incidence of death or disability at 6 months after extracorporeal membrane oxygenation in Australia: a prospective, multicentre, registry-embedded cohort study.体外膜肺氧合治疗 6 个月后澳大利亚患者的病死率或残疾率:一项前瞻性、多中心、登记嵌入式队列研究。
Lancet Respir Med. 2022 Nov;10(11):1038-1048. doi: 10.1016/S2213-2600(22)00248-X. Epub 2022 Sep 26.
6
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南:美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
7
Mechanical Left Ventricular Unloading in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation.机械左心室卸载在接受静脉动脉体外膜肺氧合的患者中。
J Am Coll Cardiol. 2022 Apr 5;79(13):1239-1250. doi: 10.1016/j.jacc.2022.01.032.
8
Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry.COVID-19 患者的体外膜肺氧合治疗:国际体外生命支持组织注册研究的结果演变。
Lancet. 2021 Oct 2;398(10307):1230-1238. doi: 10.1016/S0140-6736(21)01960-7. Epub 2021 Sep 29.
9
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
10
Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association.心血管医学中统计学报告的推荐:美国心脏协会的特别报告。
Circulation. 2021 Jul 27;144(4):e70-e91. doi: 10.1161/CIRCULATIONAHA.121.055393. Epub 2021 May 25.